Donepezil minimally effective for patients with vascular dementia

Article Type
Changed
Fri, 01/18/2019 - 08:40
Display Headline
Donepezil minimally effective for patients with vascular dementia
PRACTICE RECOMMENDATIONS

Donepezil (Aricept—a potent acetylcholin-esterase inhibitor) had small effects on mentation for patients with mild to moderate vascular dementia as measured by validated instruments of cognition.

Donepezil’s side effects are similar to placebo at 5 mg but double at 10 mg, with no improvement in the patient’s cognition. Even though this medication was minimally effective, there are no other highly effective medical treatments for vascular dementia. Therefore, if a patient chooses a trial of donepezil, the lower, 5-mg dose should be offered.

The medication’s effect is likely a class effect and not an individual drug effect; therefore, rivastigmine (Exelon) and galantamine(Reminyl) are 2 other acetylcholinesterase inhibitors that should also be considered. Cost is similar for all 3 drugs at about $130.00 per month.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Black S, Román GC, Geldmacher DS, et al; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323–2332.

Kenneth H. Johnson, DO
Family Practice Residency Program, Eastern Maine Medical Center, Bangor, Maine. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(3)
Publications
Topics
Page Number
172-188
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Black S, Román GC, Geldmacher DS, et al; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323–2332.

Kenneth H. Johnson, DO
Family Practice Residency Program, Eastern Maine Medical Center, Bangor, Maine. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Black S, Román GC, Geldmacher DS, et al; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323–2332.

Kenneth H. Johnson, DO
Family Practice Residency Program, Eastern Maine Medical Center, Bangor, Maine. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

Donepezil (Aricept—a potent acetylcholin-esterase inhibitor) had small effects on mentation for patients with mild to moderate vascular dementia as measured by validated instruments of cognition.

Donepezil’s side effects are similar to placebo at 5 mg but double at 10 mg, with no improvement in the patient’s cognition. Even though this medication was minimally effective, there are no other highly effective medical treatments for vascular dementia. Therefore, if a patient chooses a trial of donepezil, the lower, 5-mg dose should be offered.

The medication’s effect is likely a class effect and not an individual drug effect; therefore, rivastigmine (Exelon) and galantamine(Reminyl) are 2 other acetylcholinesterase inhibitors that should also be considered. Cost is similar for all 3 drugs at about $130.00 per month.

 
PRACTICE RECOMMENDATIONS

Donepezil (Aricept—a potent acetylcholin-esterase inhibitor) had small effects on mentation for patients with mild to moderate vascular dementia as measured by validated instruments of cognition.

Donepezil’s side effects are similar to placebo at 5 mg but double at 10 mg, with no improvement in the patient’s cognition. Even though this medication was minimally effective, there are no other highly effective medical treatments for vascular dementia. Therefore, if a patient chooses a trial of donepezil, the lower, 5-mg dose should be offered.

The medication’s effect is likely a class effect and not an individual drug effect; therefore, rivastigmine (Exelon) and galantamine(Reminyl) are 2 other acetylcholinesterase inhibitors that should also be considered. Cost is similar for all 3 drugs at about $130.00 per month.

 
Issue
The Journal of Family Practice - 53(3)
Issue
The Journal of Family Practice - 53(3)
Page Number
172-188
Page Number
172-188
Publications
Publications
Topics
Article Type
Display Headline
Donepezil minimally effective for patients with vascular dementia
Display Headline
Donepezil minimally effective for patients with vascular dementia
Sections
Disallow All Ads
Article PDF Media

Geranium extract reduces bronchitis symptoms

Article Type
Changed
Fri, 01/18/2019 - 08:40
Display Headline
Geranium extract reduces bronchitis symptoms
PRACTICE RECOMMENDATIONS

This study provides very good evidence that geranium root (Pelargonium sidoides) extract significantly reduces the severity and duration of acute bronchitis symptoms with minimal side effects. Clinicians should recommend this extract for acute bronchitis.

Umcka, a geranium root extract, is marketed in the US, but clinicians should keep in mind that purity and standardization of herbal products are not regulated, and that this report did not include children or pregnant women.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (Eps 7630) in adults with acute bronchitis. A randomized, double-blind, placebo controlled trial. Phytomedicine 2003; 10(Suppl 4): S7–S17.

Mark Gwynne, DO
Warren Newton, MD, MPH
Department of Family Medicine, University of North Carolina at Chapel Hill. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(3)
Publications
Topics
Page Number
172-188
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (Eps 7630) in adults with acute bronchitis. A randomized, double-blind, placebo controlled trial. Phytomedicine 2003; 10(Suppl 4): S7–S17.

Mark Gwynne, DO
Warren Newton, MD, MPH
Department of Family Medicine, University of North Carolina at Chapel Hill. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (Eps 7630) in adults with acute bronchitis. A randomized, double-blind, placebo controlled trial. Phytomedicine 2003; 10(Suppl 4): S7–S17.

Mark Gwynne, DO
Warren Newton, MD, MPH
Department of Family Medicine, University of North Carolina at Chapel Hill. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

This study provides very good evidence that geranium root (Pelargonium sidoides) extract significantly reduces the severity and duration of acute bronchitis symptoms with minimal side effects. Clinicians should recommend this extract for acute bronchitis.

Umcka, a geranium root extract, is marketed in the US, but clinicians should keep in mind that purity and standardization of herbal products are not regulated, and that this report did not include children or pregnant women.

 
PRACTICE RECOMMENDATIONS

This study provides very good evidence that geranium root (Pelargonium sidoides) extract significantly reduces the severity and duration of acute bronchitis symptoms with minimal side effects. Clinicians should recommend this extract for acute bronchitis.

Umcka, a geranium root extract, is marketed in the US, but clinicians should keep in mind that purity and standardization of herbal products are not regulated, and that this report did not include children or pregnant women.

 
Issue
The Journal of Family Practice - 53(3)
Issue
The Journal of Family Practice - 53(3)
Page Number
172-188
Page Number
172-188
Publications
Publications
Topics
Article Type
Display Headline
Geranium extract reduces bronchitis symptoms
Display Headline
Geranium extract reduces bronchitis symptoms
Sections
Disallow All Ads
Article PDF Media

Epinephrine is efficacious for outpatient treatment of bronchiolitis

Article Type
Changed
Fri, 01/18/2019 - 08:40
Display Headline
Epinephrine is efficacious for outpatient treatment of bronchiolitis
PRACTICE RECOMMENDATIONS

Epinephrine provides small short-term benefits in ambulatory patients with acute bronchiolitis; however, it is not definitely better than albuterol.

Data do not support using epinephrine for inpatient bronchiolitis. This question remains unanswered due to the small size of the studies included in this meta-analysis and the absence of a reliable clinical scoring system to measure response in bronchiolitis.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med 2003; 157:957–964.

Joseph J. Saseen, PharmD
University of Colorado Health Sciences Center, Departments of Clinical Pharmacy and Family Medicine, Denver. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(3)
Publications
Topics
Page Number
172-188
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med 2003; 157:957–964.

Joseph J. Saseen, PharmD
University of Colorado Health Sciences Center, Departments of Clinical Pharmacy and Family Medicine, Denver. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med 2003; 157:957–964.

Joseph J. Saseen, PharmD
University of Colorado Health Sciences Center, Departments of Clinical Pharmacy and Family Medicine, Denver. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

Epinephrine provides small short-term benefits in ambulatory patients with acute bronchiolitis; however, it is not definitely better than albuterol.

Data do not support using epinephrine for inpatient bronchiolitis. This question remains unanswered due to the small size of the studies included in this meta-analysis and the absence of a reliable clinical scoring system to measure response in bronchiolitis.

 
PRACTICE RECOMMENDATIONS

Epinephrine provides small short-term benefits in ambulatory patients with acute bronchiolitis; however, it is not definitely better than albuterol.

Data do not support using epinephrine for inpatient bronchiolitis. This question remains unanswered due to the small size of the studies included in this meta-analysis and the absence of a reliable clinical scoring system to measure response in bronchiolitis.

 
Issue
The Journal of Family Practice - 53(3)
Issue
The Journal of Family Practice - 53(3)
Page Number
172-188
Page Number
172-188
Publications
Publications
Topics
Article Type
Display Headline
Epinephrine is efficacious for outpatient treatment of bronchiolitis
Display Headline
Epinephrine is efficacious for outpatient treatment of bronchiolitis
Sections
Disallow All Ads
Article PDF Media

3-year interval between Pap smears adequate for women with prior negative results

Article Type
Changed
Fri, 01/18/2019 - 08:40
Display Headline
3-year interval between Pap smears adequate for women with prior negative results
PRACTICE RECOMMENDATIONS

This study predicts that among women aged 30 to 64 years with 3 recent, negative Papanicolaou (Pap) smears, extending the interval for cervical cancer screening from 1 to 3 years would lead to an excess risk of cervical cancer of 3 in 100,000.

For women aged 30 to 44 years, preventing 1 case of cervical cancer through yearly Pap smears would require an additional 69,665 Pap smears and 3861 colposcopies (compared with screening 3 years after the last negative Pap smear). Clinicians should feel comfortable extending the interval for Pap smears from 1 to 3 years in women with prior normal results and a high likelihood of follow-up.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349:1501–1509.

Michael Ohl, MD
Kevin Y. Kane, MD, MSPH
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(3)
Publications
Topics
Page Number
172-188
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349:1501–1509.

Michael Ohl, MD
Kevin Y. Kane, MD, MSPH
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003; 349:1501–1509.

Michael Ohl, MD
Kevin Y. Kane, MD, MSPH
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

This study predicts that among women aged 30 to 64 years with 3 recent, negative Papanicolaou (Pap) smears, extending the interval for cervical cancer screening from 1 to 3 years would lead to an excess risk of cervical cancer of 3 in 100,000.

For women aged 30 to 44 years, preventing 1 case of cervical cancer through yearly Pap smears would require an additional 69,665 Pap smears and 3861 colposcopies (compared with screening 3 years after the last negative Pap smear). Clinicians should feel comfortable extending the interval for Pap smears from 1 to 3 years in women with prior normal results and a high likelihood of follow-up.

 
PRACTICE RECOMMENDATIONS

This study predicts that among women aged 30 to 64 years with 3 recent, negative Papanicolaou (Pap) smears, extending the interval for cervical cancer screening from 1 to 3 years would lead to an excess risk of cervical cancer of 3 in 100,000.

For women aged 30 to 44 years, preventing 1 case of cervical cancer through yearly Pap smears would require an additional 69,665 Pap smears and 3861 colposcopies (compared with screening 3 years after the last negative Pap smear). Clinicians should feel comfortable extending the interval for Pap smears from 1 to 3 years in women with prior normal results and a high likelihood of follow-up.

 
Issue
The Journal of Family Practice - 53(3)
Issue
The Journal of Family Practice - 53(3)
Page Number
172-188
Page Number
172-188
Publications
Publications
Topics
Article Type
Display Headline
3-year interval between Pap smears adequate for women with prior negative results
Display Headline
3-year interval between Pap smears adequate for women with prior negative results
Sections
Disallow All Ads
Article PDF Media

Posttraumatic Stress Disorder: A Sign of Weakness or of Strength?

Article Type
Changed
Tue, 12/13/2016 - 12:08
Display Headline
Posttraumatic Stress Disorder: A Sign of Weakness or of Strength?

Article PDF
Author and Disclosure Information

Dennis H. Grant, MD

Dr. Grant is the clinical coordinator of the outpatient Post Traumatic Stress Disorder Clinic at Carl T. Hayden VA Medical Center in Phoenix, AZ.

Issue
Federal Practitioner - 21(3)
Publications
Topics
Page Number
53
Legacy Keywords
mental health, postdeployment health, posttraumatic stress disorder, PTSDmental health, postdeployment health, posttraumatic stress disorder, PTSD
Sections
Author and Disclosure Information

Dennis H. Grant, MD

Dr. Grant is the clinical coordinator of the outpatient Post Traumatic Stress Disorder Clinic at Carl T. Hayden VA Medical Center in Phoenix, AZ.

Author and Disclosure Information

Dennis H. Grant, MD

Dr. Grant is the clinical coordinator of the outpatient Post Traumatic Stress Disorder Clinic at Carl T. Hayden VA Medical Center in Phoenix, AZ.

Article PDF
Article PDF

Issue
Federal Practitioner - 21(3)
Issue
Federal Practitioner - 21(3)
Page Number
53
Page Number
53
Publications
Publications
Topics
Article Type
Display Headline
Posttraumatic Stress Disorder: A Sign of Weakness or of Strength?
Display Headline
Posttraumatic Stress Disorder: A Sign of Weakness or of Strength?
Legacy Keywords
mental health, postdeployment health, posttraumatic stress disorder, PTSDmental health, postdeployment health, posttraumatic stress disorder, PTSD
Legacy Keywords
mental health, postdeployment health, posttraumatic stress disorder, PTSDmental health, postdeployment health, posttraumatic stress disorder, PTSD
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Conjunctivitis: Diagnostic usefulness of signs and symptoms unknown

Article Type
Changed
Fri, 01/18/2019 - 08:41
Display Headline
Conjunctivitis: Diagnostic usefulness of signs and symptoms unknown
PRACTICE RECOMMENDATIONS

Despite recommendations in ophthalmologic texts for differentiating bacterial from viral conjunctivitis, no research supports the usefulness of any signs or symptoms to make this distinction. This raises validity questions about treatment studies based on clinically diagnosed bacterial conjunctivitis.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Rietveld RP, van Weert HCPM, ter Riet G, and Bindels PJE. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. BMJ 2003; 327:789.

Eric M. Rotert, MD
Beth Potter, MD
Department of Family Medicine, University of Wisconsin–Madison. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(2)
Publications
Topics
Page Number
93-105
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Rietveld RP, van Weert HCPM, ter Riet G, and Bindels PJE. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. BMJ 2003; 327:789.

Eric M. Rotert, MD
Beth Potter, MD
Department of Family Medicine, University of Wisconsin–Madison. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Rietveld RP, van Weert HCPM, ter Riet G, and Bindels PJE. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. BMJ 2003; 327:789.

Eric M. Rotert, MD
Beth Potter, MD
Department of Family Medicine, University of Wisconsin–Madison. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

Despite recommendations in ophthalmologic texts for differentiating bacterial from viral conjunctivitis, no research supports the usefulness of any signs or symptoms to make this distinction. This raises validity questions about treatment studies based on clinically diagnosed bacterial conjunctivitis.

 
PRACTICE RECOMMENDATIONS

Despite recommendations in ophthalmologic texts for differentiating bacterial from viral conjunctivitis, no research supports the usefulness of any signs or symptoms to make this distinction. This raises validity questions about treatment studies based on clinically diagnosed bacterial conjunctivitis.

 
Issue
The Journal of Family Practice - 53(2)
Issue
The Journal of Family Practice - 53(2)
Page Number
93-105
Page Number
93-105
Publications
Publications
Topics
Article Type
Display Headline
Conjunctivitis: Diagnostic usefulness of signs and symptoms unknown
Display Headline
Conjunctivitis: Diagnostic usefulness of signs and symptoms unknown
Sections
Disallow All Ads
Article PDF Media

Four-year prostate cancer screening interval is effective

Article Type
Changed
Fri, 01/18/2019 - 08:41
Display Headline
Four-year prostate cancer screening interval is effective
PRACTICE RECOMMENDATIONS

This study found a relatively low rate of prostate cancer diagnoses during a 4-year interval between screenings in Danish men aged 55 to 74 years. For those men choosing to undergo prostate cancer screening, these results show that annual screening is not necessary. Whether screening reduces prostate cancer-specific mortality is yet to be determined.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Van der Cruijsen-Koeter, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95:1462–1466.

Kenneth G. Schellhase, MD, MPH
Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(2)
Publications
Topics
Page Number
93-105
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Van der Cruijsen-Koeter, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95:1462–1466.

Kenneth G. Schellhase, MD, MPH
Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Van der Cruijsen-Koeter, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95:1462–1466.

Kenneth G. Schellhase, MD, MPH
Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

This study found a relatively low rate of prostate cancer diagnoses during a 4-year interval between screenings in Danish men aged 55 to 74 years. For those men choosing to undergo prostate cancer screening, these results show that annual screening is not necessary. Whether screening reduces prostate cancer-specific mortality is yet to be determined.

 
PRACTICE RECOMMENDATIONS

This study found a relatively low rate of prostate cancer diagnoses during a 4-year interval between screenings in Danish men aged 55 to 74 years. For those men choosing to undergo prostate cancer screening, these results show that annual screening is not necessary. Whether screening reduces prostate cancer-specific mortality is yet to be determined.

 
Issue
The Journal of Family Practice - 53(2)
Issue
The Journal of Family Practice - 53(2)
Page Number
93-105
Page Number
93-105
Publications
Publications
Topics
Article Type
Display Headline
Four-year prostate cancer screening interval is effective
Display Headline
Four-year prostate cancer screening interval is effective
Sections
Disallow All Ads
Article PDF Media

Azithromycin (3 days) better than amoxicillin-clavulanate (10 days) for sinusitis?

Article Type
Changed
Fri, 01/18/2019 - 08:41
Display Headline
Azithromycin (3 days) better than amoxicillin-clavulanate (10 days) for sinusitis?
PRACTICE RECOMMENDATIONS

It is reasonable to try a 3-day course of azithromycin (Zithromax) 500 mg/d for patients with a firm diagnosis of acute bacterial sinusitis.

However, keep in mind that antibiotics in general do not provide a clinically meaningful advantage when compared with placebo. Azithromycin is well tolerated, and patients are more likely to complete a 3-day course than a 10-day one. Recall that amoxicillin is as effective as macrolides clinically, and that most cases of sinusitis are not bacterial.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. Randomized double-blind study comparing 3- and 6-day regi-mens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–2774.

Marc R. Via, MD
Department of Family and Community Medicine, Scott & White Memorial Hospital, Texas A & M University System Health Science Center College of Medicine, Temple, Tex. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(2)
Publications
Topics
Page Number
93-105
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. Randomized double-blind study comparing 3- and 6-day regi-mens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–2774.

Marc R. Via, MD
Department of Family and Community Medicine, Scott & White Memorial Hospital, Texas A & M University System Health Science Center College of Medicine, Temple, Tex. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. Randomized double-blind study comparing 3- and 6-day regi-mens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–2774.

Marc R. Via, MD
Department of Family and Community Medicine, Scott & White Memorial Hospital, Texas A & M University System Health Science Center College of Medicine, Temple, Tex. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

It is reasonable to try a 3-day course of azithromycin (Zithromax) 500 mg/d for patients with a firm diagnosis of acute bacterial sinusitis.

However, keep in mind that antibiotics in general do not provide a clinically meaningful advantage when compared with placebo. Azithromycin is well tolerated, and patients are more likely to complete a 3-day course than a 10-day one. Recall that amoxicillin is as effective as macrolides clinically, and that most cases of sinusitis are not bacterial.

 
PRACTICE RECOMMENDATIONS

It is reasonable to try a 3-day course of azithromycin (Zithromax) 500 mg/d for patients with a firm diagnosis of acute bacterial sinusitis.

However, keep in mind that antibiotics in general do not provide a clinically meaningful advantage when compared with placebo. Azithromycin is well tolerated, and patients are more likely to complete a 3-day course than a 10-day one. Recall that amoxicillin is as effective as macrolides clinically, and that most cases of sinusitis are not bacterial.

 
Issue
The Journal of Family Practice - 53(2)
Issue
The Journal of Family Practice - 53(2)
Page Number
93-105
Page Number
93-105
Publications
Publications
Topics
Article Type
Display Headline
Azithromycin (3 days) better than amoxicillin-clavulanate (10 days) for sinusitis?
Display Headline
Azithromycin (3 days) better than amoxicillin-clavulanate (10 days) for sinusitis?
Sections
Disallow All Ads
Article PDF Media

Antidepressant treatment reduces poststroke mortality

Article Type
Changed
Fri, 01/18/2019 - 08:41
Display Headline
Antidepressant treatment reduces poststroke mortality
PRACTICE RECOMMENDATIONS

Treatment with either fluoxetine or nortripty-line for 12 weeks during the first 6 months poststroke reduced the mortality risk of both depressed and nondepressed patients. Strong consideration should be given to treating clinically depressed and nondepressed post-stroke patients who are at significant risk of developing depression (family history or personal history of mood disorders) with antidepressant medication.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of anti-depressants. Am J Psychiatry 2003; 160:1823–1829.

David S. Chun, PharmD
St. Louis College of Pharmacy, St. Louis, Mo. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(2)
Publications
Topics
Page Number
93-105
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of anti-depressants. Am J Psychiatry 2003; 160:1823–1829.

David S. Chun, PharmD
St. Louis College of Pharmacy, St. Louis, Mo. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of anti-depressants. Am J Psychiatry 2003; 160:1823–1829.

David S. Chun, PharmD
St. Louis College of Pharmacy, St. Louis, Mo. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

Treatment with either fluoxetine or nortripty-line for 12 weeks during the first 6 months poststroke reduced the mortality risk of both depressed and nondepressed patients. Strong consideration should be given to treating clinically depressed and nondepressed post-stroke patients who are at significant risk of developing depression (family history or personal history of mood disorders) with antidepressant medication.

 
PRACTICE RECOMMENDATIONS

Treatment with either fluoxetine or nortripty-line for 12 weeks during the first 6 months poststroke reduced the mortality risk of both depressed and nondepressed patients. Strong consideration should be given to treating clinically depressed and nondepressed post-stroke patients who are at significant risk of developing depression (family history or personal history of mood disorders) with antidepressant medication.

 
Issue
The Journal of Family Practice - 53(2)
Issue
The Journal of Family Practice - 53(2)
Page Number
93-105
Page Number
93-105
Publications
Publications
Topics
Article Type
Display Headline
Antidepressant treatment reduces poststroke mortality
Display Headline
Antidepressant treatment reduces poststroke mortality
Sections
Disallow All Ads
Article PDF Media

Vaccinations containing thimerosal do not increase rates of autism

Article Type
Changed
Fri, 01/18/2019 - 08:41
Display Headline
Vaccinations containing thimerosal do not increase rates of autism
PRACTICE RECOMMENDATIONS

This retrospective cohort study found that autism rates in children receiving vaccines containing thimerosal were not statistically different than for children receiving thimerosal-free vaccines.

This study refutes any connection between the thimerosal preservative and autistic disorders, but does not evaluate the risk of autistic disorders in vaccinated children compared with those who are not vaccinated. No routine pediatric vaccinations currently used in the United States contain thimerosal.

 
Article PDF
Author and Disclosure Information

Practice Recommendations from Key Studies

Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763–1766.

Jennifer J. Buescher, MD
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Issue
The Journal of Family Practice - 53(2)
Publications
Topics
Page Number
93-105
Sections
Author and Disclosure Information

Practice Recommendations from Key Studies

Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763–1766.

Jennifer J. Buescher, MD
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Author and Disclosure Information

Practice Recommendations from Key Studies

Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763–1766.

Jennifer J. Buescher, MD
Department of Family and Community Medicine, University of Missouri–Columbia. E-mail: [email protected].

Article PDF
Article PDF
PRACTICE RECOMMENDATIONS

This retrospective cohort study found that autism rates in children receiving vaccines containing thimerosal were not statistically different than for children receiving thimerosal-free vaccines.

This study refutes any connection between the thimerosal preservative and autistic disorders, but does not evaluate the risk of autistic disorders in vaccinated children compared with those who are not vaccinated. No routine pediatric vaccinations currently used in the United States contain thimerosal.

 
PRACTICE RECOMMENDATIONS

This retrospective cohort study found that autism rates in children receiving vaccines containing thimerosal were not statistically different than for children receiving thimerosal-free vaccines.

This study refutes any connection between the thimerosal preservative and autistic disorders, but does not evaluate the risk of autistic disorders in vaccinated children compared with those who are not vaccinated. No routine pediatric vaccinations currently used in the United States contain thimerosal.

 
Issue
The Journal of Family Practice - 53(2)
Issue
The Journal of Family Practice - 53(2)
Page Number
93-105
Page Number
93-105
Publications
Publications
Topics
Article Type
Display Headline
Vaccinations containing thimerosal do not increase rates of autism
Display Headline
Vaccinations containing thimerosal do not increase rates of autism
Sections
Disallow All Ads
Article PDF Media